NCT06411639View on ClinicalTrials.gov

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

November 25, 2024

Primary Completion Date

December 17, 2025

Study Completion Date

June 24, 2028

Conditions

Sjogren DiseaseSystemic Lupus Erythematosus

Interventions

DRUG

ianalumab

ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.